当前位置： SCI文献检索 > BREAST CANCER RESEARCH AND TREATMENT期刊下所有文献 > Immunohistologic and histochemical methods for detection of steroid binding in breast cancer: a reappraisal.

Immunohistologic and histochemical methods for detection of steroid binding in breast cancer: a reappraisal.

Abstract：

:A review of the current literature on immunohistologic and histochemical methods for the detection of steroid hormone binding sites in breast cancer, reveals that many, but not all of the criteria for establishing hormone-receptor binding interactions have been met. These include tissue specificity, binding between labeled ligands and soluble receptor in vitro, correlations between histochemical and biochemical assays, as well as between histologic procedures and tumor hormone responsiveness. However, histochemical binding phenomena do not appear to follow classical receptor dogma in regard to the concentration of ligand required, or specificity of binding as determined by competitive binding assays. It is concluded that these histologic techniques may be detecting classical receptor that may be reacting differently than would be expected from biochemical analyses, Types II and III binding sites, and/or organelle and membrane-bound receptors. Certainly no current method should presently be promoted as a laboratory method for the detection of classical receptor. New immunocytologic procedures employing specific, antireceptor sera currently under development, may obviate many of the criticisms leveled against earlier methods.

journal_name

Breast Cancer Res Treat

journal_title

Breast cancer research and treatment

authors

Pertschuk LP,Tobin EH,Carter AC,Eisenberg KB,Leo VC,Gaetjens E,Bloom ND

doi

10.1007/BF01806746

subject

Has Abstract

pub_date

1981-01-01 00:00:00

pages

297-314

issue

4

eissn

0167-6806

issn

1573-7217

journal_volume

1

pub_type

杂志文章

相关文献

BREAST CANCER RESEARCH AND TREATMENT文献大全
  • Cytogenetic evaluation of 20 sporadic breast cancer patients and their first degree relatives.

    abstract：:Many genetic abnormalities disclosed even in somatic cells like peripheral blood lymphocytes may mark footprint(s) of malignancy(ies). The present cytogenetic study on peripheral blood lymphocytes of sporadic breast cancer patients (n = 20) and their first degree relatives (n = 39) reports abnormalities of chromosomes...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1005951125574

    authors： Trivedi AH,Roy SK,Bhachech SH,Patel RK,Dalal AA,Bhatavdekar JM,Patel DD

    更新日期：1998-03-01 00:00:00

  • Structural and functional studies of insulin receptors in human breast cancer.

    abstract：:We characterized the structure and the function of insulin receptors isolated from 10 human breast cancer specimens. We observed that the insulin receptor content, as determined by a specific radioimmunoassay, was four fold increased in human breast cancer tissue when compared to normal breast tissues. In both cancer ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF00662403

    authors： Frittitta L,Vigneri R,Papa V,Goldfine ID,Grasso G,Trischitta V

    更新日期：1993-01-01 00:00:00

  • Expression of coxsackie-adenovirus receptor is related to estrogen sensitivity in breast cancer.

    abstract：:This study analyzes the relationship between coxsackie-adenovirus receptor (CAR) expression (transmembrane and soluble isoforms) and hormone sensitivity in 95 breast cancers. Furthermore, prognostic significance of the expression of the various CAR isoforms was investigated. In addition, inducibility of CAR expression...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-008-0108-0

    authors： Auer D,Reimer D,Porto V,Fleischer M,Roessler J,Wiedemair A,Marth C,Müller-Holzner E,Daxenbichler G,Zeimet AG

    更新日期：2009-07-01 00:00:00

  • Premature menopause in patients with BRCA1 gene mutation.

    abstract：:This study was undertaken with regard to the gonadotropin theory of ovarian cancer advocated in the literature and was designed to disclose specific features of ovarian morphology in carriers of the BRCA1 gene mutation. We enrolled 171 patients and divided them into two groups: A (n=90)--operated for breast cancer (30...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-006-9220-1

    authors： Rzepka-Górska I,Tarnowski B,Chudecka-Głaz A,Górski B,Zielińska D,Tołoczko-Grabarek A

    更新日期：2006-11-01 00:00:00

  • Larger axillary metastases in obese women and smokers with breast cancer--an influence by host factors on early tumor behavior.

    abstract：:To better define the influence by host factors on very early breast cancer behavior, we retrospectively analyzed nodal status, diameter of the largest axillary metastasis (M), diameter of the primary tumor (P), the M/P ratio, tumor estrogen receptor status, age, obesity, and smoking habits in 176 women with node-posit...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF00689833

    authors： Daniell HW,Tam E,Filice A

    更新日期：1993-01-01 00:00:00

  • EGF binding is quantitatively related to growth in node-positive breast cancer.

    abstract：:Number of mitoses and EGF binding were determined in parallel in biopsies of 27 lymph-node positive and of 23 lymph-node negative breast cancer patients. For node-positive patients the parameters for cell growth and EGF binding were quantitatively correlated by the equation y = P3 + P1(1- exp(- P2x]. For node-negative...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01805739

    authors： Spitzer E,Koepke K,Kunde D,Grosse R

    更新日期：1988-09-01 00:00:00

  • Mutation analysis of RAD51L1 (RAD51B/REC2) in multiple-case, non-BRCA1/2 breast cancer families.

    abstract：:Although a significant proportion of familial aggregation of breast cancer remains unexplained, many of the currently known breast cancer susceptibility genes, including BRCA1, BRCA2 and TP53, play a role in maintaining genome integrity by engaging in DNA repair. RAD51L1 is one of the five RAD51 paralogs involved in h...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1539-6

    authors： Johnson J,Healey S,Khanna KK,kConFab.,Chenevix-Trench G

    更新日期：2011-08-01 00:00:00

  • GGNBP2 suppresses triple-negative breast cancer aggressiveness through inhibition of IL-6/STAT3 signaling activation.

    abstract：BACKGROUND:Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, lacking effective targeted therapies, and whose underlying mechanisms are still unclear. The gene coding for Gametogenetin-binding protein (GGNBP2), also known as Zinc Finger Protein 403 (ZNF403), is located on chromosome 1...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-018-5052-z

    authors： Liu J,Liu L,Yagüe E,Yang Q,Pan T,Zhao H,Hu Y,Zhang J

    更新日期：2019-02-01 00:00:00

  • Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer.

    abstract：:The high potency and selectivity of new aromatase inhibitors has translated to greater efficacy and improved tolerability in comparison with established second-line hormonal agents for advanced breast cancer in phase III clinical trials. Two pharmacological studies are reported which assess the use of one of these inh...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章

    doi：10.1023/a:1006289811540

    authors： Dowsett M,Doody D,Miall S,Howes A,English J,Coombes RC

    更新日期：1999-07-01 00:00:00

  • Long-term outcome in young women with breast cancer: a population-based study.

    abstract：PURPOSE:Whether young age at diagnosis of breast cancer is an independent risk factor for death remains controversial, and the question whether young age should be considered in treatment decisions is still to be answered. METHODS:From a population-based cohort of 22,017 women with breast cancer, all women <35 years (...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-016-3983-9

    authors： Fredholm H,Magnusson K,Lindström LS,Garmo H,Fält SE,Lindman H,Bergh J,Holmberg L,Pontén F,Frisell J,Fredriksson I

    更新日期：2016-11-01 00:00:00

  • A phase II trial of weekly paclitaxel, 5-fluorouracil, and leucovorin as first-line treatment for metastatic breast cancer.

    abstract：PURPOSE:This phase II multicenter trial evaluated the efficacy and toxicity of weekly paclitaxel, 5-fluorouracil, and leucovorin administered as first-line therapy for metastatic breast cancer. PATIENTS AND METHODS:The study enrolled 155 women with pathologically confirmed and measurable metastatic adenocarcinoma of t...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1023/a:1021384318470

    authors： Loesch DM,Asmar L,Canfield VA,Parker GA,Hynes HE,Ellis PG,Ferri WA Jr,Robert NJ

    更新日期：2003-01-01 00:00:00

  • MiR-28 regulates Nrf2 expression through a Keap1-independent mechanism.

    abstract：:NF-E2-related factor 2 (Nrf2) is an important transcription factor involved in antioxidant response. Nrf2 binds antioxidant response elements (ARE) within promoters of genes encoding detoxification enzymes (e.g., NAD (P) H-quinone oxidoreductase 1 (NQO1)) leading to their transcriptional activation. Nrf2 function is r...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1604-1

    authors： Yang M,Yao Y,Eades G,Zhang Y,Zhou Q

    更新日期：2011-10-01 00:00:00

  • One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery).

    abstract：:Genetic testing enables women at risk for hereditary breast and/or ovarian cancer to find out whether they have inherited the gene mutation (BRCA1/BRCA2), and if so, to opt for frequent surveillance and/or prophylactic surgery (bilateral mastectomy and/or oophorectomy). Here, a follow-up is described for 63 healthy wo...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1015269620265

    authors： Lodder LN,Frets PG,Trijsburg RW,Meijers-Heijboer EJ,Klijn JG,Seynaeve C,van Geel AN,Tilanus MM,Bartels CC,Verhoog LC,Brekelmans CT,Burger CW,Niermeijer MF

    更新日期：2002-05-01 00:00:00

  • Evolution in practice patterns of axillary management following mastectomy in patients with 1-2 positive sentinel nodes.

    abstract：PURPOSE:The optimal management of breast cancer patients with a positive sentinel lymph node (SLN) who undergo mastectomy remains controversial. This study aimed to describe treatment patterns of patients with positive SLNs who undergo mastectomy using a large population-based database. METHODS:The NCDB was queried fo...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-019-05243-7

    authors： Weiss A,Lin H,Babiera GV,Bedrosian I,Shaitelman SF,Shen Y,Kuerer HM,Mittendorf EA,Caudle AS,Hunt KK,Hwang RF

    更新日期：2019-07-01 00:00:00

  • PACAP(6-38) is a PACAP receptor antagonist for breast cancer cells.

    abstract：:The effects of pituitary adenylate cyclase activating polypeptide (PACAP) analogs were investigated using breast cancer cells. 125I-PACAP-27 bound with high affinity (Kd = 5 nM) to T47D cells (Bmax = 29,000 per cell). Specific 125I-PACAP-27 binding was inhibited half maximally by PACAP-27, PACAP-38, PACAP(6-38) and PA...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1006262611290

    authors： Leyton J,Gozes Y,Pisegna J,Coy D,Purdom S,Casibang M,Zia F,Moody TW

    更新日期：1999-07-01 00:00:00

  • A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.

    abstract：PURPOSE:The Janus-associated kinase (JAK)/signal transducer and activator of transcription pathway is a key regulator of inflammatory signaling, associated with tumorigenesis, cell survival, and progression. This randomized phase 2 trial evaluated the efficacy and safety of the addition of ruxolitinib, a JAK1/JAK2 inhi...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s10549-018-4770-6

    authors： O'Shaughnessy J,DeMichele A,Ma CX,Richards P,Yardley DA,Wright GS,Kalinsky K,Steis R,Diab S,Kennealey G,Geschwindt R,Jiang W,Rugo HS

    更新日期：2018-08-01 00:00:00

  • Exercise during puberty and NMU induced mammary tumorigenesis in rats.

    abstract：:Previously we have shown that exercising rats prior to administration of 50 mg NMU/kg (high dose) significantly decreased tumor multiplicity, but not incidence or latency. We hypothesized that the dose of NMU saturated the system such that the exercise intervention was overshadowed. Therefore, the purpose of this inve...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1005838721890

    authors： Whittal-Strange KS,Chadan S,Parkhouse WS

    更新日期：1998-01-01 00:00:00

  • Trastuzumab improves tumor perfusion and vascular delivery of cytotoxic therapy in a murine model of HER2+ breast cancer: preliminary results.

    abstract：:To employ in vivo imaging and histological techniques to identify and quantify vascular changes early in the course of treatment with trastuzumab in a murine model of HER2+ breast cancer. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) was used to quantitatively characterize vessel perfusion/permeabilit...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-016-3680-8

    authors： Sorace AG,Quarles CC,Whisenant JG,Hanker AB,McIntyre JO,Sanchez VM,Yankeelov TE

    更新日期：2016-01-01 00:00:00

  • Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer.

    abstract：:This study compared the efficacy and safety of a 3-monthly 10.8-mg depot goserelin (Zoladex(TM)) injection with the current 3.6 mg monthly dose in pre-menopausal Japanese women with estrogen receptor-positive (ER+) early breast cancer. This was a multicenter, open-label, randomized study. Primary endpoint was a non-in...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10549-010-1332-y

    authors： Masuda N,Iwata H,Rai Y,Anan K,Takeuchi T,Kohno N,Takei H,Yanagita Y,Noguchi S

    更新日期：2011-04-01 00:00:00

  • Can diffusion-weighted MR imaging and contrast-enhanced MR imaging precisely evaluate and predict pathological response to neoadjuvant chemotherapy in patients with breast cancer?

    abstract：:Clinical evidence regarding the value of MRI for therapy responses assessment in breast cancer is increasing. The objective of this study is to compare the diagnostic capability of diffusion-weighted MR imaging (DW-MRI) and contrast-enhanced MR imaging (CE-MRI) to evaluate and predict pathological response in breast c...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,meta分析,评审

    doi：10.1007/s10549-012-2033-5

    authors： Wu LM,Hu JN,Gu HY,Hua J,Chen J,Xu JR

    更新日期：2012-08-01 00:00:00

  • Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic review.

    abstract：BACKGROUND:Due to the high rate of febrile neutropenia (FN) with docetaxel-cyclophosphamide (DC) chemotherapy, primary FN prophylaxis is recommended. However, the optimal choice of prophylaxis [i.e., granulocyte-colony stimulating factors (G-CSF) or antibiotics] is unknown. A systematic review was performed to address ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/s10549-016-4028-0

    authors： Fernandes R,Mazzarello S,Stober C,Vandermeer L,Dudani S,Ibrahim MF,Majeed H,Perdrizet K,Shorr R,Hutton B,Fergusson D,Clemons M

    更新日期：2017-01-01 00:00:00

  • Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice.

    abstract：:One of the most efficacious primary therapies in HER2-positive breast cancer was published by the M.D. Anderson group in 2005. This randomized trial evaluated the addition of trastuzumab to a taxane-anthracycline based chemotherapy. Despite largely significant differences in pathological complete response (pCR) in the...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章

    doi：10.1007/s10549-012-2149-7

    authors： Pernas S,Gil-Gil M,de Olza MO,Gumà A,Climent F,Petit A,Pla MJ,García-Tejedor A,López-Ojeda A,Falo C,Fernandez-Otega A,Mesia C,Pérez-Martin FJ,Urruticoechea A,Germà JR

    更新日期：2012-08-01 00:00:00

  • Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer.

    abstract：BACKGROUND:The estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) statuses are frequently discordant between the primary tumor and metastatic lesions in metastatic breast cancer. This can have important therapeutic implications. PATIENTS AND METHODS:In all, 541 pati...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05746-8

    authors： Walter V,Fischer C,Deutsch TM,Ersing C,Nees J,Schütz F,Fremd C,Grischke EM,Sinn P,Brucker SY,Schneeweiss A,Hartkopf AD,Wallwiener M

    更新日期：2020-08-01 00:00:00

  • Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts.

    abstract：:The present preclinical study was designed to evaluate a new combination therapy comprised of the aromatase inhibitor anastrozole (ANA) and the oral fluoropyrimidines, UFT and S-1 against the estrogen receptor (ER)-positive human breast cancer cell line MCF-7/Arom 14, which was stably transfected with the cDNA of huma...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-010-1141-3

    authors： Nukatsuka M,Saito H,Nakagawa F,Abe M,Uchida J,Shibata J,Matsuo K,Noguchi S,Kiniwa M

    更新日期：2011-07-01 00:00:00

  • DNA-repair genetic polymorphisms and risk of breast cancer in Cyprus.

    abstract：:The DNA repair pathway is known to play a role in the etiology of breast cancer. A number of studies have demonstrated that common germline variants in genes involved in the DNA repair pathway influence breast cancer risk. To assess whether alterations in DNA repair genes contribute to breast cancer, we genotyped 12 s...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-008-0084-4

    authors： Loizidou MA,Michael T,Neuhausen SL,Newbold RF,Marcou Y,Kakouri E,Daniel M,Papadopoulos P,Malas S,Hadjisavvas A,Kyriacou K

    更新日期：2009-06-01 00:00:00

  • HER2 status in a population-derived breast cancer cohort: discordances during tumor progression.

    abstract：:This retrospective study investigates the correlation of intra-individual HER2 status between primary breast cancers and corresponding recurrences in a population derived cohort. The REMARK criteria were used as reference. In 151 breast cancer patients, primary tumors were analyzed for HER2 status on histopathology se...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-010-1029-2

    authors： Wilking U,Karlsson E,Skoog L,Hatschek T,Lidbrink E,Elmberger G,Johansson H,Lindström L,Bergh J

    更新日期：2011-01-01 00:00:00

  • Mismatch repair defective breast cancer in the hereditary nonpolyposis colorectal cancer syndrome.

    abstract：:Whether or not breast cancer can be a feature of the hereditary nonpolyposis colorectal cancer (HNPCC) syndrome has been debated. In order to clarify if defective mismatch repair (MMR) may indeed play a role in breast cancer, we used the Danish HNPCC register to identify all breast cancers that occurred in MMR gene mu...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-009-0449-3

    authors： Jensen UB,Sunde L,Timshel S,Halvarsson B,Nissen A,Bernstein I,Nilbert M

    更新日期：2010-04-01 00:00:00

  • GDNF induces RET-SRC-HER2-dependent growth in trastuzumab-sensitive but SRC-independent growth in resistant breast tumor cells.

    abstract：:We investigated the role of glial cell line-derived neurotrophic factor (GDNF) in compensating trastuzumab (TZMB)-induced apoptosis in HER2+ breast cancer (BC) cells using xenograft tumors. We generated BC xenografts in nude mice using samples from three patients selected based on their HER2 status and response to TZM...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-016-4078-3

    authors： Gardaneh M,Shojaei S,Kaviani A,Behnam B

    更新日期：2017-04-01 00:00:00

  • Circulating tumor cells in non-metastatic triple-negative breast cancer.

    abstract：:Circulating tumor cells (CTCs) can be identified in approximately 25 % of stage I-III breast cancer patients; CTCs presence is a predictor of poor outcome in metastatic breast cancer, but little is known regarding the prognostic significance of CTCs in non-metastatic triple-negative breast cancer (TNBC) patients. The ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-014-3103-7

    authors： Karhade M,Hall C,Mishra P,Anderson A,Kuerer H,Bedrosian I,Krishnamurthy S,Lucci A

    更新日期：2014-09-01 00:00:00

  • Phase II study of amonafide in advanced breast cancer.

    abstract：:Twenty-eight patients with advanced breast cancer refractory to prior hormone and/or first-line chemotherapy (with or without anthracycline drugs) were treated with the investigational agent amonafide at a dose of 800 mg/m2 intravenously over 3 hours repeated every 4 weeks. Five objective tumour responses of 5.0 month...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章

    doi：10.1007/BF01833358

    authors： Scheithauer W,Dittrich C,Kornek G,Haider K,Linkesch W,Gisslinger H,Depisch D

    更新日期：1991-12-01 00:00:00